Potency, efficacy and durability of DNA/DNA, DNA/ protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Mazumder, Saumyabrata ^a   Maji, Mithun ^a   Das, Amrita ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN; GLYCOPROTEIN 63; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LEISHMANIA VACCINE; UNCLASSIFIED DRUG; GLYCOPROTEIN GP63, LEISHMANIA; METALLOPROTEINASE; PROTOZOAL DNA; PROTOZOAL PROTEIN; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA DNA VACCINATION; DNA IMMUNIZATION; DNA PRIME PROTEIN BOOST VACCINATION; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; GENE VECTOR; GENETIC IMMUNIZATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN VACCINATION; PROTEIN PURIFICATION; RISK REDUCTION; VISCERAL LEISHMANIASIS; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CHO CELL; CRICETULUS; EVALUATION; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; SYRIAN HAMSTER; TREATMENT OUTCOME;

LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MAMMALIA; MURINAE; MUS; PROTOZOA;

ANIMALS; ANTIBODY FORMATION; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DNA, PROTOZOAN; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MESOCRICETUS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TREATMENT OUTCOME;

EID: 79551634103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014644     Document Type: Article

References (60)

1. Herwaldt BL (1999) Leishmaniasis. Lancet 354: 1191-1199.
2. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
3. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, et al. (2002) Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 35: 581-586.
4. Tang DC, DeVit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.
5. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
6. Cox GJ, Zamb TJ, Babiuk LA (1993) Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 67: 5664-5667.
7. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
8. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15: 617-648.
9. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, et al. (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with L. major. J Exp Med 186: 1137-1147.
10. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, et al. (1998) Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 9: 1899-1907.
11. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, et al. (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 4103-4108.
12. Gurunathan S, Wu CY, Freidag BL, Seder RA (2000) DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12: 442-447.
13. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, et al. (2000) Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19: 764-778.
14. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, et al. (2001) Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 98: 10817-10822.
15. Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351.
16. Sedegah M, Brice GT, Rogers WO, Doolan DL, Charoenvit Y, et al. (2002) Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun 70: 3493-3499.
17. Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, et al. (2004) Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 22: 3622-3627.
18. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, et al. (2008) Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
19. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. (2008) Crosssubtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26: 3947-3957.
20. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, et al. (2002) A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20: 1226-1231.
21. Lange UG, Mastroeni P, Blackwell JM, Stober CB (2004) DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 72: 4924-4928.
22. Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R (2005) A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 191: 2130-2137.
23. Rafati S, Zahedifard F, Nazgouee F (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 2169-2175.
24. Dondji B, Pérez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D (2005) Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73: 5286-5289.
25. Rafati S, Ghaemimanesh F, Zahedifard F (2006) Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine 24: 3290-3297.
26. Lepay DA, Nogueira N, Cohn Z (1983) Surface antigens of Leishmania donovani promastigotes. J Exp Med 157: 1562-1572.
27. Colomer-Gould V, Glvao Quintao L, Keithly J, Nogueira N (1985) A common major surface antigen on amastigotes and promastigotes of Leishmania species. J Exp Med 162: 902-916.
28. Bhowmick S, Ravindran R, Ali N (2008) gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 76: 1003-1015.
29. Afrin F, Ali N (1997) Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 65: 2371-2377.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
31. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF (1998) CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 160: 5898-5906.
32. Mazumdar T, Anam K, Ali N (2004) A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22: 1162-1171.
33. Gurunathan S, Prussin C, Sacks DL, Seder RA (1998) Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4: 1409-1415.
34. Banerjee A, De M, Ali N (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 181: 1386-1398.
35. Titus RG, Marchand M, Boon T, Louis JA (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.
36. Seder RA, Gazzinelli R, Sher A, Paul WE (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming Proc Natl Acad Sci U S A 90: 10188-10192.
37. Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM (1994) Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 179: 447-456.
38. Xu D, Liew FY (1994) Genetic vaccination against leishmaniasis. Vaccine 12: 1534-1536.
39. Xu D, Liew FY (1995) Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84: 173-176.
40. Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM (2003) DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21: 2161-2168.
41. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K (2004) A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22: 1631-1639.
42. Sachdeva R, Banerjea AC, Malla N, Dubey ML (2009) Immunogenicity and efficacy of single antigen Gp63, polytope and polytope HSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. PLoS One 4: e7880.
43. Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, et al. (2001) The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166: 5122-5128.
44. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, et al. (2002) Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 195: 1565-1573.
45. Klinman DM, Yamshchikov G, Ishigatsubo Y (1997) Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158: 3635-3639.
46. Sato Y, Roman M, Tighe H, Lee D, Corr M, et al. (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354.
47. Kojima Y, Xin KQ, Ooki T, Hamajima K, Oikawa T, et al. (2002) Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 20: 2857-2865.
48. Kwissa M, Amara RR, Robinson HL, Moss B, Alkan S, et al. (2007) Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204: 2733-2746.
49. Haldar JP, Ghose S, Saha KC, Ghose AC (1983) Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702-707.
50. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, et al. (1994) Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956.
51. Howard JG, Liew FY (1984) Mechanisms of acquired immunity in leishmaniasis. Philos Trans R Soc Lond B Biol Sci 307: 87-98.
52. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, et al. (2005) Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812-819.
53. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM (1998) Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 28: 669-680.
54. Murray HW, Hariprashad J, Coffman RL (1997) Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med 185: 867-874.
55. Murray HW, Nathan CF (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-746.
56. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, et al. (1987) Experimental visceral leishmaniasis: production of interleukin 2 and interferongamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol 138: 2290-2297.
57. Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, et al. (1993) Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61: 1069-1073.
58. Basu R, Bhaumik S, Basu JM, Naskar K, De T, et al. (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171.
59. Bhaumik S, Basu R, Sen S, Naskar K, Roy S (2009) KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27: 1306-1316.
60. Bhowmick S, Ali N (2009) Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PloS one 4: e5820.